{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:55:53Z","timestamp":1740146153143,"version":"3.37.3"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["K23AI110532"],"award-info":[{"award-number":["K23AI110532"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG028748"],"award-info":[{"award-number":["P30AG028748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000124"],"award-info":[{"award-number":["UL1TR000124"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30AI028697"],"award-info":[{"award-number":["5P30AI028697"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["M0128RR000865"],"award-info":[{"award-number":["M0128RR000865"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32MH080634"],"award-info":[{"award-number":["T32MH080634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000445"],"award-info":[{"award-number":["UL1TR000445"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0170515","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T18:37:40Z","timestamp":1485283060000},"page":"e0170515","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial"],"prefix":"10.1371","volume":"12","author":[{"given":"Catherine N.","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Hulgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger L.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan E.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1097\/QAD.0b013e3282efad32","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"H Wand","year":"2007","journal-title":"AIDS. England"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"FJ Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"N Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"N Friis-M\u00f8ller","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"VA Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4102\/sajhivmed.v14i1.100","article-title":"Overview of HIV-related lipodystrophy","volume":"14","author":"TM Rossouw","year":"2013","journal-title":"South Afr J HIV Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.metabol.2010.09.011","article-title":"Body fat redistribution and metabolic abnormalities in HIV-infected patients on HAART: novel insights into pathophysiology and emerging opportunities for treatment","volume":"60","author":"F Magkos","year":"2011","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"ref8","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"A Carr","year":"2003","journal-title":"AIDS. England"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1468-1293.2009.00766.x","article-title":"Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: Relationships with serum markers of oxidation and inflammation","volume":"11","author":"S Parra","year":"2010","journal-title":"HIV Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/QAI.0b013e3181b939e5","article-title":"Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study","volume":"52","author":"MS Boger","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/aid.2011.0232","article-title":"Serum Leptin Level Mediates the Association of Body Composition and Serum C-Reactive Protein in HIV-Infected Persons on Antiretroviral Therapy","volume":"28","author":"JR Koethe","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0378-4347(93)80161-V","article-title":"Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry","volume":"612","author":"JD Morrow","year":"1993","journal-title":"J Chromatogr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2004.08.019","article-title":"Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic\/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer","volume":"334","author":"LJ Murphey","year":"2004","journal-title":"Anal Biochem. United States"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-4347(93)E0432-P","article-title":"Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry","volume":"653","author":"VC Daniel","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"ref15","first-page":"113","article-title":"Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress","volume":"433","author":"GL Milne","year":"2007","journal-title":"Methods Enzymol. United States"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1089\/ars.2006.8.1379","article-title":"Isoprostanes and related compounds: update 2006","volume":"8","author":"GL Milne","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/erc.09.91","article-title":"Vascular biology of eicosanoids and atherogenesis","volume":"7","author":"D Pratico","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tips.2005.10.001","article-title":"Thromboxane, prostacyclin and isoprostanes: Therapeutic targets in atherogenesis","volume":"26","author":"JM Dogn\u00e9","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2008.19.7970","article-title":"Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women\u2019s Health Study","volume":"27","author":"Q Dai","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1542\/peds.2008-0735","article-title":"Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase","volume":"122","author":"F Martino","year":"2008","journal-title":"Pediatrics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.CIR.0000116761.93647.30","article-title":"Urinary 8-iso-Prostaglandin F2\u03b1 as a Risk Marker in Patients with Coronary Heart Disease: A Matched Case-Control Study","volume":"109","author":"E Schwedhelm","year":"2004","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MCA.0b013e3282f0efa5","article-title":"Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis","volume":"18","author":"I Basarici","year":"2007","journal-title":"Coron Artery Dis"},{"key":"ref23","first-page":"2073","article-title":"Prostaglandin F2 alpha plasma concentration predicts glycemic control and oxidation status in patients with type 2 diabetes mellitus","volume":"60","author":"M Nakhjavani","year":"2014","journal-title":"Clin Lab. Germany"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/1055-9965.EPI-09-0680","article-title":"Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women\u2019s health study","volume":"18","author":"LM Dong","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/1352458512457721","article-title":"Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course","volume":"19","author":"E Sbardella","year":"2013","journal-title":"Mult Scler"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1086\/379776","article-title":"Oxidant stress is increased during treatment of human immunodeficiency virus infection","volume":"37","author":"T Hulgan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1158\/1078-0432.CCR-05-0733","article-title":"Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers","volume":"11","author":"ND Gross","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199505043321804","article-title":"Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage","volume":"332","author":"JD Morrow","year":"1995","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1089\/apc.2012.0135","article-title":"A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy","volume":"26","author":"JE Lake","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3851\/IMP1809","article-title":"Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients","volume":"16","author":"J Vecchiet","year":"2011","journal-title":"Antivir Ther. England"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/HJH.0b013e3280287a83","article-title":"Effects of telmisartan on fat distribution in individuals with the metabolic syndrome","volume":"25","author":"M Shimabukuro","year":"2007","journal-title":"J Hypertens"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/HJH.0b013e3280287a83","article-title":"Effects of telmisartan on fat distribution in individuals with the metabolic syndrome","volume":"25","author":"M Shimabukuro","year":"2007","journal-title":"J Hypertens"},{"key":"ref33","article-title":"Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients","author":"D Chujo","year":"2007","journal-title":"Hypertension research: official journal of the Japanese Society of Hypertension"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"G Derosa","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/hr.2009.95","article-title":"Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma","volume":"32","author":"A Nakano","year":"2009","journal-title":"Hypertens Res"},{"key":"ref36","article-title":"A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial","volume":"8","author":"JE Lake","year":"2013","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","volume":"357","author":"J Falutz","year":"2007","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2012.09.030","article-title":"Measurement of F2- isoprostanes and isofurans using gas chromatography-mass spectrometry","volume":"59","author":"GL Milne","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0009340","article-title":"Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT","volume":"5","author":"TJ Montine","year":"2010","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2014.07.017","article-title":"Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study","volume":"7","author":"V Shah R","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3851\/IMP1990","article-title":"Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy","volume":"17","author":"MS Boger","year":"2011","journal-title":"Antivir Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1373\/clinchem.2004.037630","article-title":"Plasma F2-isoprostanes and coronary artery calcification: The CARDIA study","volume":"51","author":"M Gross","year":"2005","journal-title":"Clin Chem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.ATV.0000058402.34138.11","article-title":"Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham study","volume":"23","author":"JF Keaney","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1310\/hct1003-181","article-title":"Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults","volume":"10","author":"LA Redhage","year":"2009","journal-title":"HIV Clin Trials"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/hq0302.104515","article-title":"Greater oxidative stress in healthy young men compared with premenopausal women","volume":"22","author":"T Ide","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-85-4-447","article-title":"Menopause and risk of cardiovascular disease: the Framingham study","volume":"85","author":"WB Kannel","year":"1976","journal-title":"Ann Intern Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0952-3278(02)00229-6","article-title":"Effects of nicotine on thromboxane\/prostacyclin balance in myocardial ischemia","volume":"68","author":"R Nemr","year":"2003","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"803095","DOI":"10.1155\/2014\/803095","article-title":"Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial","volume":"2014","author":"T Hulgan","year":"2014","journal-title":"Mediators Inflamm"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4172\/2155-6113.1000174","article-title":"Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy","volume":"3","author":"M Tungsiripat","year":"2012","journal-title":"J AIDS Clin Res"},{"key":"ref50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085230","article-title":"Prostaglandin e2 reduces the release and infectivity of new cell-free virions and cell-to-cell HIV-1 transfer","volume":"9","author":"MI Clemente","year":"2014","journal-title":"PLoS One"},{"key":"ref51","first-page":"1","article-title":"Prostaglandin E2 promotes features of replicative senescence in chronically activated human CD8+ T cells","volume":"9","author":"JP Chou","year":"2014","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1940-6207.CAPR-11-0496","article-title":"The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E 2 levels","volume":"5","author":"DW Fitzgerald","year":"2012","journal-title":"Cancer Prev Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1940-6207.CAPR-13-0040","article-title":"Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women","volume":"6","author":"S Kim","year":"2013","journal-title":"Cancer Prev Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1940-6207.CAPR-11-0426","article-title":"Urinary prostaglandin E2 metabolite and risk for colorectal adenoma","volume":"5","author":"MJ Shrubsole","year":"2012","journal-title":"Cancer Prev Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1940-6207.CAPR-09-0093","article-title":"Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients","volume":"2","author":"VD Kekatpure","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00431-010-1157-z","article-title":"Increased plasma isoprostane is associated with visceral fat, high molecular weight adiponectin, and metabolic complications in obese children","volume":"169","author":"S Araki","year":"2010","journal-title":"Eur J Pediatr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0170515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:56:20Z","timestamp":1589018180000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0170515"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0170515","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,1,24]]}}}